News >

Usmani Discusses Emergence of CAR T-Cell Therapy in Myeloma

Gina Columbus @ginacolumbusonc
Published: Monday, Jul 31, 2017

Saad Z. Usmani, MD

Saad Z. Usmani, MD
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a potential therapeutic option in the pipeline of multiple myeloma agents, as early studies have shown encouraging activity.

For example, results of a small phase I trial, presented at the 22nd Annual European Hematology Association Congress, showed that patients with multiple myeloma achieved a response following treatment with an active dose of bb2121, an investigational anti–B-cell maturation antigen (BCMA) CAR T-cell construct.1

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication